Clomiphene Citrate Salt Clomiphene Citrate Salt

Structural formula

• Numbering system
• Physical property data
• Toxicological data
• Ecological data
• Molecular structure data
• Computing chemical data
• More
  • Properties and Stability
  • Storage method
  • Synthesis method
  • Purpose

Numbering system

CAS number:50-41-9

MDL number:MFCD00058322

EINECS number:200-035-3

RTECS number:YE0875000

BRN number:None

PubChem number:24892851

Physical property data

1. Character:White or milky white crystalline powder

2. Density (g/mL ,25/4℃): Undetermined

3. Relative vapor density (g /mL,AIR= 1): Undetermined

4. Melting point (ºC):116.5-118°C

5. Boiling point (ºC,Normal pressure): Undetermined

6. Boiling point (ºC, 5.2 kPa): Undetermined

7. Refractive index:Undetermined

8. Flash point (ºC): Undetermined

9. Specific optical rotation (º ): Undetermined

10. Autoignition point or ignition temperature (ºC): Undetermined

11. Vapor pressure (kPa, 25 ºC): Undetermined10 , Isotope atomic number: 0

11. Determine the number of atomic stereocenters: 0

12. The number of uncertain atomic stereocenters: 0

13. Determine the number of stereocenters of chemical bonds: 1

14. Uncertain number of chemical bond stereocenters: 0

15. Number of covalent bond units: 2

Properties and stability

None

Storage method

Sealed in4℃Save in a dry place and away from light.

Synthesis method

4-Hydroxybenzophenone and diethylaminoethyl chloride hydrochloride The salt is etherified to obtain p-diethylaminooxybenzophenone. After addition, hydrolysis, elimination, and chlorination, chlorostilbene amine is produced.[（911-45-5]), and finally use citric acid to form a salt to obtain the product.

Purpose

This product is an anti-estrogen (fertility inducer), used in gynecological diseases such as functional uterine bleeding, polycystic ovaries, menstrual disorders and drug-induced amenorrhea.

amily: 宋体; mso-font-kerning: 0pt”>

Purpose

This product is an anti-estrogen (fertility inducer), used in gynecological diseases such as functional uterine bleeding, polycystic ovaries, menstrual disorders and drug-induced amenorrhea.